PMID- 21894244
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211020
IS  - 1475-0708 (Print)
IS  - 1744-831X (Electronic)
IS  - 1475-0708 (Linking)
VI  - 8
IP  - 4
DP  - 2011 Jul
TI  - mTOR inhibitors in renal cell carcinoma.
PG  - 359-367
AB  - The mammalian target of rapamycin (mTOR) is a downstream effector of the 
      PI3-K/Akt/mTOR pathway. Allosteric inhibitors of mTOR, everolimus and 
      temsirolimus, have shown promising clinical activity in advanced renal cell 
      carcinoma but their effect is far from durable and only a subset of patients 
      experience substantial benefit from these agents. The PI3-K/Akt/mTOR pathway 
      represents an intricate network of fine regulation and feedback loops, and 
      resistance to allosteric mTOR inhibitors may be embedded within this complexity. 
      In this article we highlight the molecular elements of the PI3-K/Akt/mTOR 
      pathway, the clinical experience with everolimus and temsirolimus in advanced 
      renal cell carcinoma, and the future directions in terms of sequential therapy, 
      combinational therapy and development of novel therapeutic agents.
FAU - Battelli, Chiara
AU  - Battelli C
AD  - Division of Hematology & Oncology, Beth Israel Deaconess Medical Center, 330 
      Brookline Avenue, Boston, MA 02215, USA.
FAU - Cho, Daniel C
AU  - Cho DC
LA  - eng
GR  - K08 CA142890/CA/NCI NIH HHS/United States
GR  - K08 CA142890-02/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - England
TA  - Therapy
JT  - Therapy (London, England : 2004)
JID - 101230448
PMC - PMC3164983
MID - NIHMS316956
EDAT- 2011/09/07 06:00
MHDA- 2011/09/07 06:01
PMCR- 2012/05/01
CRDT- 2011/09/07 06:00
PHST- 2011/09/07 06:00 [entrez]
PHST- 2011/09/07 06:00 [pubmed]
PHST- 2011/09/07 06:01 [medline]
PHST- 2012/05/01 00:00 [pmc-release]
AID - 10.2217/thy.11.32 [doi]
PST - ppublish
SO  - Therapy. 2011 Jul;8(4):359-367. doi: 10.2217/thy.11.32.